A dose-escalation study of docetaxel, oxaliplatin, and S-1 (DOS) as a first-line therapy for patients with unresectable metastatic gastric cancer

被引：0
|
作者：
Yasushi Sato
Tamotsu Sagawa
Hiroyuki Ohnuma
Masahiro Hirakawa
Yasuo Takahashi
Kyoko Hamaguchi
Koshi Fujikawa
Takayuki Nobuoka
Koichi Okamoto
Hiroshi Miyamoto
Naoki Muguruma
Ichiro Takemasa
Tetsuji Takayama
机构：
[1] Tokushima University Graduate School of Biomedical Sciences,Department of Community Medicine for Gastroenterology and Oncology
[2] Hokkaido Cancer Center,Department of Gastroenterology
[3] Sapporo Medical University School of Medicine,Department of Medical Oncology
[4] Tokushima University Graduate School of Biomedical Sciences,Department of Gastroenterology and Oncology
[5] Sapporo Medical University School of Medicine,Department of Surgery, Surgical Oncology and Science
来源：
Cancer Chemotherapy and Pharmacology | 2019年 / 83卷
关键词：
Gastric cancer; S-1; Docetaxel; Oxaliplatin; Phase I; Conversion therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：161 / 167
页数：6
相关论文
共 50 条
  • [1] A dose-escalation study of docetaxel, oxaliplatin, and S-1 (DOS) as a first-line therapy for patients with unresectable metastatic gastric cancer
    Sato, Yasushi
    Sagawa, Tamotsu
    Ohnuma, Hiroyuki
    Hirakawa, Masahiro
    Takahashi, Yasuo
    Hamaguchi, Kyoko
    Fujikawa, Koshi
    Nobuoka, Takayuki
    Okamoto, Koichi
    Miyamoto, Hiroshi
    Muguruma, Naoki
    Takemasa, Ichiro
    Takayama, Tetsuji
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (01) : 161 - 167
  • [2] A dose-escalation study of docetaxel, oxaliplatin and S-1 (DOS) as a first-line therapy for patients with unresectable metastatic gastric cancer.
    Sato, Yasushi
    Sagawa, Tamotsu
    Takahashi, Yasuo
    Ohnuma, Hiroyuki
    Hamaguchi, Kyoko
    Hirakawa, Masahiro
    Fujikawa, Koshi
    Okamoto, Koichi
    Miyamoto, Hiroshi
    Muguruma, Naoki
    Takayama, Tetsuji
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [3] A phase II study of S-1 and oxaliplatin as first-line therapy for patients with recurrent or metastatic gastric cancer
    Kim, H.
    Lee, G.
    Kim, H.
    Lee, O.
    Hwang, I.
    Kang, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] A PHASE II STUDY OF S-1 AND OXALIPLATIN AS FIRST-LINE THERAPY FOR PATIENTS WITH RECURRENT OR METASTATIC GASTRIC CANCER
    Kim, H. G.
    Kang, M.
    Kim, S.
    Lee, S. I.
    Lee, G.
    Kang, J. H.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 182 - 182
  • [5] A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer
    Sato, Yasushi
    Ohnuma, Hiroyuki
    Hirakawa, Masahiro
    Takahashi, Minoru
    Osuga, Takahiro
    Okagawa, Yutaka
    Murase, Kazuyuki
    Takada, Kohichi
    Kawano, Yutaka
    Iyama, Satoshi
    Hayashi, Tsuyoshi
    Sato, Tsutomu
    Miyanishi, Koji
    Takimoto, Rishu
    Kobune, Masayoshi
    Okita, Kenji
    Mizuguchi, Toru
    Furuhata, Tomohisa
    Hirata, Koichi
    Kato, Junji
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (03) : 587 - 594
  • [6] A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer
    Yasushi Sato
    Hiroyuki Ohnuma
    Masahiro Hirakawa
    Minoru Takahashi
    Takahiro Osuga
    Yutaka Okagawa
    Kazuyuki Murase
    Kohichi Takada
    Yutaka Kawano
    Satoshi Iyama
    Tsuyoshi Hayashi
    Tsutomu Sato
    Koji Miyanishi
    Rishu Takimoto
    Masayoshi Kobune
    Kenji Okita
    Toru Mizuguchi
    Tomohisa Furuhata
    Koichi Hirata
    Junji Kato
    [J]. Cancer Chemotherapy and Pharmacology, 2015, 75 : 587 - 594
  • [7] Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer
    Kouroussis, C
    Androulakis, N
    Kakolyris, S
    Souglakos, J
    Kotsakis, T
    Mavroudis, D
    Katsogridakis, K
    Vardakis, N
    Hatzidaki, D
    Samonis, G
    Vlachonikolis, J
    Georgoulias, V
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) : 862 - 869
  • [8] A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab (bev) as a first-line therapy for patients with metastatic colorectal cancer
    Sato, Yasushi
    Ohnuma, Hiroyuki
    Hirakawa, Masahiro
    Takahashi, Minoru
    Osuga, Takahiro
    Takada, Kohichi
    Hayashi, Tsuyoshi
    Sato, Tsutomu
    Miyanishi, Koji
    Takimoto, Rishu
    Kobune, Masayoshi
    Okita, Kenji
    Furuhata, Tomohisa
    Hirata, Koichi
    Kato, Junji
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [9] Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer
    Hyeong Su Kim
    Min-Hee Ryu
    Dae Young Zang
    Baek-Yeol Ryoo
    Dae Hyun Yang
    Ji Woong Cho
    Man Sup Lim
    Min-Jeong Kim
    Boram Han
    Dae Ro Choi
    Jung Han Kim
    Joo Young Jung
    Hunho Song
    Choong Kee Park
    Yoon-Koo Kang
    [J]. Gastric Cancer, 2016, 19 : 579 - 585
  • [10] Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer
    Kim, Hyeong Su
    Ryu, Min-Hee
    Zang, Dae Young
    Ryoo, Baek-Yeol
    Yang, Dae Hyun
    Cho, Ji Woong
    Lim, Man Sup
    Kim, Min-Jeong
    Han, Boram
    Choi, Dae Ro
    Kim, Jung Han
    Jung, Joo Young
    Song, Hunho
    Park, Choong Kee
    Kang, Yoon-Koo
    [J]. GASTRIC CANCER, 2016, 19 (02) : 579 - 585
12345